Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Aviron -- Ignore unavailable to you. Want to Upgrade?

To: John Finley who wrote (504)	11/16/1999 1:41:00 PM
From: RWReeves	Respond to of 645

The other Question that I have not been able to answer is why Gilead didn't move on Tamiflu approval and neither did AVIR. Since that's the case, then will it take CORR-like "brute-force-get-to-market-and-sell-the-stuff" to make AVIR rise? What happened to efficient markets discount the future into today and all that? I like AVIR; it's cheap and getting cheaper for what's there but I grudgingly planning to take the pay-off when AVIR eventually gets munched or starts earning real sales revenues. That's pretty sad, a milestone in this dot-com era. RWR